Is Neurocrine Biosciences (NBIX) Still Cheap As INGREZZA Data And Earnings Outlook Lift Sentiment?

Fresh data on patient reported outcomes for INGREZZA has pushed Neurocrine Biosciences (NBIX) back into focus for investors, as quality of life metrics intersect with a recently strengthened earnings outlook.

That backdrop has been reflected in the tape. Neurocrine Biosciences has logged a 16.17% 7 day share price return and an 18.55% 30 day share price return, building on a 20.10% year to date share price gain and a 92.37% 5 year total shareholder return. INGREZZA data, new CRENESSITY education efforts and the latest earnings update have sharpened sentiment around the stock’s longer term potential.

Spot opportunities in neurological and biotech momentum by scanning the hand picked 19 high quality undiscovered gems that share some of the same quality traits investors see in Neurocrine Biosciences today.

After a sharp rerating on stronger INGREZZA data and a firmer earnings profile, Neurocrine Biosciences now carries higher expectations. Do the current numbers still leave enough upside in the risk reward for new buyers?

Most Popular Narrative: 18% Undervalued

The analyst consensus Narrative on Simply Wall St views Neurocrine Biosciences as worth $206.81 per share, compared with a last close of $168.86, and ties that gap directly to how well the multi product story is executed.

The current valuation implies that Neurocrine Biosciences'' share price already reflects INGREZZA’s IRA related pricing drag and VYKAT XR concerns, yet still assigns meaningful upside if the company proves this multiproduct, late stage pipeline story is as undervalued as the narrative claims.

See why 51 investors see Neurocrine Biosciences as 18% undervalued.

For investors weighing the recent INGREZZA data, CRENESSITY traction and the psychiatry pipeline against current expectations, that fair value implies the market is still debating how much of the earnings and revenue forecasts to credit today, especially with a 7.49% discount rate applied to those future cash flows.

Result: Fair Value of $206.81 (UNDERVALUED)

Still, two pressure points could derail that 18% undervalued narrative: tougher INGREZZA pricing and reimbursement, and any VYKAT XR safety or uptake setbacks that reset expectations.

Find out about the key risks to this Neurocrine Biosciences narrative.

Next Steps

Sentiment around Neurocrine Biosciences is clearly leaning positive, so the real question is how quickly you pressure test that optimism against the underlying figures and decide where you stand. To see what others view as the upside case, take a closer look at the 4 key rewards.

Looking for more investment ideas beyond Neurocrine Biosciences?

If you only stop at Neurocrine Biosciences, you risk missing other opportunities that fit your style and could sharpen your overall portfolio approach.

• Scan for potential mispriced opportunities by checking the 33 high quality undervalued stocks that combine solid fundamentals with room for sentiment to catch up.
• Build a steadier income stream by reviewing the 6 dividend fortresses that focus on richer yields backed by stronger balance sheets.
• Strengthen your downside protection by assessing the 30 resilient stocks with low risk scores that score better on resilience and financial robustness.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com